Quick Answer
InMed Pharmaceuticals Inc. reported Net Income of -$8.16 million for fiscal year 2025.
InMed Pharmaceuticals Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$8.16M | -6.3% |
| 2024 | -$7.68M | +3.4% |
| 2023 | -$7.95M | +57.3% |
| 2022 | -$18.60M | -82.3% |
| 2021 | -$10.20M | -14.1% |
| 2020 | -$8.94M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$2.03M | +21.2% | -17.4% |
| September 30, 2025 | -$1.73M | -2.9% | +18.6% |
| March 31, 2025 | -$2.12M | -23.1% | +17.6% |
| December 31, 2024 | -$2.58M | -74.2% | -53.5% |
| September 30, 2024 | -$1.68M | +33.9% | +2.6% |
| March 31, 2024 | -$1.72M | +13.8% | -16.6% |
| December 31, 2023 | -$1.48M | +29.6% | +41.7% |
| September 30, 2023 | -$2.54M | +27.7% | -27.0% |
- InMed Pharmaceuticals Inc. showed a decrease of -6.3% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, InMed Pharmaceuticals Inc.’s net income has grown by 8.7% (from -$8.94 million to -$8.16 million).
- The most recent figure is from InMed Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: